SNY vs VNDA: fair value comparison
Sanofi and Vanda Pharmaceuticals Inc. · Updated 2026-08-31
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, VNDA currently sits closer to the top of our discount ranking. SNY carries the stronger quality grade.
| SNY | VNDA | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $42.95 | $5.23 |
| 12-month range | $41.63–$47.40 | $4.47–$8.25 |
| Sector rank | #41 of 113 Healthcare | #36 of 113 Healthcare |
| Quality grade | B | D |
| Leverage | Low | Low |
| Margin trend | Expanding | — |
| Revenue growth | Modest | — |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Downtrend | Mixed |
| DCF cross-check | Overvalued | — |
| 52-week position | The bottom quarter | The bottom quarter |
Full single-stock breakdowns: SNY fair value analysis · VNDA fair value analysis